1. Evaluating LDL-C Recommendations

3. 2013 ACC/AHA Cholesterol Guidelines Four Statin Benefit Groups Identified

5. IMPROVE-IT Simvastatin 40 mg vs Simvastatin/Ezetimibe 40 mg/10 mg

6. IMPROVE-IT (cont)

7. IMPROVE-IT (cont)

8. IMPROVE-IT vs CTT Ezetimibe vs Statin Benefit

12. JUPITER and TNT Trials Evidence That Lower LDL-C Is Better

13. ODYSSEY LONG-TERM Alirocumab 150 mg vs Placebo 2:1

14. ODYSSEY LONG-TERM (cont)

15. OSLER Evolocumab + Standard Therapy vs Standard Therapy Alone 2:1

17. ODYSSEY LONG-TERM AEs by Achieved LDL-C

19. GAUSS-2 and ODYSSEY ALTERNATIVE PCSK9 Inhibitors Well Tolerated by Statin-intolerant Patients

20. PROVE-IT TIMI 22 Intensive vs Moderate Statin Therapy After ACS

21. Meta-analysis of Statin Trials Risk of Major CV Events by LDL-C Level

23. Ongoing PCSK9 Inhibitor CVD Outcomes Trials

24. Abbreviations

25. Abbreviations (cont)

26. Abbreviations (cont)

27. Abbreviations (cont)

28. References

29. References (cont)

30. References (cont)

31. References (cont)

32. References (cont)

33. References (cont)

34. References (cont)